Gentian USA Inc  

215 N Eola Dr
Orlando,  FL  32801

United States
http://www.gentian.com
  • Booth: 3201

Gentian’s goal is to increase efficiency and decrease costs associated with human and veterinary diagnostic testing in areas of kidney, infectious, inflammatory, and cardiovascular diseases. In combining 20+ years of industry experience with proprietary technologies, Gentian has established itself as a leader in Particle-Enhanced Turbidimetric Immunoassay (PETIA) development. The current product portfolio includes cystatin C (510(k)-cleared/CE marked), plasma and serum calprotectin (CE marked/US Research Use Only), canine CRP and fecal calprotectin assays. Gentian also welcomes opportunities for collaboration with OEMs. Gentian products can be used without additional investment in instrumentation because assays are designed for use on all major clinical chemistry analyzers. Production, R&D, marketing and distribution of immunoassays are performed at our headquarters in Norway and are supported globally by subsidiaries in the US and Sweden and a representative office in China.


 Press Releases

  • Gentian Diagnostics has been a leading manufacturer of turbidimetric cystatin C immunoassays since 2006. The Gentian Cystatin C Immunoassay is an IVD test for quantitative determination of cystatin C in human plasma and serum, supporting an early detection of reduced kidney function.
    The assay has been FDA 510(k) cleared since 2007 and is and CE-marked and IVDR certified.
     
    Cystatin C on instruments already in your lab
    Our assay is compatible with a wide range of clinical chemistry analyzers and ensures high inter-instrument accuracy for both serum and plasma samples.
    • Abbott Laboratories (CLIA for Alinity c)
    • Beckman Coulter (CLIA for AU480, AU 5800, AU 680, Immage 800, DxC 500AU, DxC 700AU)
    • Mindray
    • Roche
    • Siemens Healthineers
     
    Calibrator standardization
    The calibrator for the Gentian Cystatin C Immunoassay is available in two versions, one-level calibra­tor for auto-dilution or a 6-point pre-diluted calibrator kit. Both types of calibrators are standardized against the international calibrator standard ERM-DA471/IFCC.

    Assay Performance
    Sample type Serum, plasma
    Assay type PETIA
    Format Two reagents, ready to use
    Measuring range ~ 0.4 - 8.0 mg/L
    Precision1 Total CV < 4 %
    Limit of quantification1 0.43 mg/L
    Security zone 31.13 mg/L
    Standardisation Calibrated against the reference material
    ERM-DA471/IFCC

    Kidney health advocates and organizations embrace increased use of cystatin C
    Recommended by the KDIGO guidelines (2024), the National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Task Force (2021), and the European Kidney Function Consortium (EKFC) (2023), cystatin C in combination with creatinine provides the most accurate assessment of glomerular filtration rate (GFR) and kidney function compared to creatinine alone. Increased use of cystatin C, alongside creatinine, is advised to offer a more reliable estimation of eGFR.
     
    Is cystatin C really that expensive? Cost-Effectiveness of scaling cystatin C testing
    The relationship between test volumes and reagent costs is tied to the operational dynamics of automated clinical chemistry analysers. The standard assay is composed of three components:
    • Test reagents
    • Quality control reagents
    • Calibration reagents
    Notably, it’s only the test reagent volume that changes depending on the number of patient samples being tested. Running more samples allows the cost of the control and calibration reagents to be spread across a larger number of tests, bringing down the overall cost of the test. For instance, a health system conducting a 10 000 cystatin C tests annually will reduce their cost per test by up to 80% compared to a hospital performing around 1000 cystatin C tests. This is due to the economies of scale achieved through increased testing volume.
    1.  
    About Gentian Diagnostics – Gentian USA Inc.
    Gentian Diagnostics, a Norwegian company, develops and manufactures open channel turbidimetric assays for clinical chemistry analyzers. We manufacture reagents for both laboratories and industry partners. Our headquarters in Norway handle R&D, production, marketing, and distribution. Global operations are supported by subsidiaries in Sweden and the US, and a representative office in China.
    Gentian USA, Inc., a wholly owned subsidiary established in 2012, serves the US market. For our US customers, our assays are shipped domestically from within the United States. 


    1Instrument specific, validation results for Roche Cobas c501

    This article may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.
     
  • ​​​​​​Pioneer study exploring the role of circulating calprotectin in autoinflammatory skin disease
    Gentian has, in collaboration with Professor Evangelos Giamarellos-Bourboulis from the University of Athens, initiated a study to explore the correlation of circulating calprotectin levels with the activity and severity of hidradenitis suppurativa (HS). In this study the plasma calprotectin levels have been measured with the Gentian GCAL® Calprotectin Immunoassay.

    HS is a chronic autoinflammatory skin condition impacting the apocrine sweat glands. Draining tunnel (dT) formation is the hallmark of HS in the affected skin. Early intervention is crucial to prevent the formation of severe scarring in affected skin, but predicting the course and advancement of the disease is challenging. The existence of a biomarker which may predict dT formation before dTs appear in skin may become a tool for early identification of severe disease and early start of the treatment. Calprotectin belongs to a S100 protein family and is composed of the subunits S100A8 and S100A9. Calprotectin is released during inflammation of activated neutrophils, monocytes and macrophages. Circulating calprotectin has been proven as an early biomarker for detection of inflammation and estimation of disease activity in various inflammatory conditions.

    In this study, calprotectin is presented for the first time as a biomarker for formation of draining tunnels in the skin. Thus, calprotectin could serve as a valuable tool for the early identification of severe HS, guiding treatment initiation and monitoring, and preventing severe inflammation and development of extensive scarring in affected skin.

    Don't miss the opportunity to delve deeper into this ground-breaking research and engage with the authors at the poster session: B-068. Plasma calprotectin as an index of draining tunnel formation in Hidradenitis suppurativa.

     
    ​​​​​​​GCAL® - Plasma and serum calprotectin
    Gentian's GCAL® assay is intended for quantitative determination of calprotectin in plasma and serum as an aid in detection and assessment of inflammation and inflammatory response to infections.

    The assay is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) that can be applied on a wide range of automated clinical chemistry analysers. Specifically using avian antibodies in this test, results in the distinct benefit avoiding common interference (namely rheumatoid factor and HAMA antibodies).

    GCAL® is the first available (since 2019) turbidimetric assay for circulating calprotectin. It is CE-marked and IVDR certified, in addition to other regional registrations. The assay is not cleared for use in the USA - for Research Use Only.

    For more information: marketing@gentian.com


     
  • ​​​​​​Recent study confirms value of serum calprotectin in detection of bacterial infections in febrile infants
    At the Hospital for Sick Children in Toronto, researchers have employed the fully automated calprotectin immunoassay GCAL® from Gentian Diagnostics to evaluate the clinical performance of serum calprotectin in identifying bacterial infections in febrile infants presenting to the emergency department (ED).

    Calprotectin belongs to the S100 protein family and is composed of the subunits S100A8 and S100A9. Calprotectin is released during the inflammatory reaction of activated neutrophils, monocytes and macrophages. The fast and direct upregulation in bacterial infections makes circulating calprotectin an early and sensitive biomarker to detect and assess infectious conditions.

    The study at the Hospital for Sick Children confirms that serum calprotectin is a valuable biomarker for differentiation between bacterial and viral infections and estimation of disease severity in febrile infants. Access to fast and accurate analysis of circulating calprotectin, combined with good clinical performance, shows the potential of this biomarker as a valuable complement to the current diagnostics of patients with bacterial infections and sepsis.

    Don't miss the opportunity to delve deeper into this ground-breaking research and engage with the authors at the poster session: A-307. Clinical utility of serum calprotectin in febrile infants presenting to the Emergency Department.
     
    GCAL® - Plasma and serum calprotectin
    Gentian's GCAL® assay is intended for quantitative determination of calprotectin in plasma and serum as an aid in detection and assessment of inflammation and inflammatory response to infections.

    The assay is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) that can be applied on a wide range of automated clinical chemistry analysers. Specifically using avian antibodies in this test, results in the distinct benefit avoiding common interference (namely rheumatoid factor and HAMA antibodies).

    GCAL® is the first available (since 2019) turbidimetric assay for circulating calprotectin. It is CE-marked and IVDR certified, in addition to other regional registrations. The assay is not cleared for use in the USA - for Research Use Only.

    More information: marketing@gentian.com
     
  • Ground-breaking assay development to measure the total level of NT-proBNP, independent of glycosylation
    Gentian Diagnostics will present new advances in the development of a turbidimetric NT-proBNP assay which is not affected by glycosylation of the protein. The assay will enable analysis of NT-proBNP on high-throughput clinical chemistry platforms and eliminate the influence of glycosylation on estimation of NT-proBNP levels.

    Glycosylation
    Multiple commercial immunoassays are available for measurement of circulating NT-proBNP levels, used as an aid in diagnosis and severity assessment of heart failure (HF). Most of these assays use antibodies that bind to the central region of NT-proBNP, which is normally glycosylated.  It has been shown that up to 80% of the NT-proBNP may be glycosylated in the central region. The glycosylation restricts antibody binding and protein detection, leading to an underestimation of NT-proBNP levels.

    Gentian’s turbidimetric NT-proBNP assay enters the final stages of optimisation phase
    Several NT-proBNP assays are already available on chemiluminescence-based diagnostic platforms. Gentian’s goal is to make NT-proBNP analysis more accessible on high-volume clinical chemistry analysers, improving cost- and workflow efficiency.

    Extensive testing of our prototype confirms the hypothesis that the glycosylation of the NT-proBNP molecule can lead to an underestimation of NT-proBNP concentrations in clinical samples, as seen with commercially available assays. Gentian's NT-proBNP assay is designed to detect endogenous NT-proBNP regardless of its glycosylation status, avoiding potential underestimation of the protein.

     
    ​​​​​​​​​​​​​​Development of an NT-proBNP assay which is not affected by glycosylation
    In the poster titled: Development and diagnostic utility of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP (A-010) we present a comparison of the Gentian’s assay with other commercially available immunoassays. This comparison focuses on effect of glycosylation on detection of NT-proBNP in patient samples.

    To investigate the effect of glycosylation, plasma samples were either non-treated or treated with a mixture of glycosidases. No significant effect of the glycosidase treatment was detected on NT-proBNP values measured by the prototype of Gentian-developed NT-proBNP assay. NT-proBNP concentrations in both treated and non-treated samples were similar and highly correlated. As a comparison, one of the commercially available assays, which uses antibodies targeting the central region of the NT-proBNP, was studied. The results show significant difference between levels measured before- and after treatment with glycosydases and confirms the underestimation of NT-proBNP concentration,.
    ​​​​​​​
    Advantages of Immunoassays Targeting Glycosylation-Free Regions of NT-proBNP in Heart Failure Diagnosis and Management
    Given the considerable variability in levels and site occupancy of O-glycosylated proteins, it is reasonable to anticipate that immunoassays targeting glycosylation-free regions of NT-proBNP may offer advantages in HF diagnosis and prognosis for specific patient groups and disease states since these assays can detect endogenous NT-proBNP regardless of its glycosylation status. 

    Don't miss the opportunity to delve deeper into this groundbreaking development and engage with us at the poster session: A-010. Development and diagnostic utility of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP

    For more information: marketing@gentian.com

     
  • The Gentian Canine CRP Immunoassay is a turbidimetric assay that has been consistently serving the global market of veterinary laboratories since 2013. The assay is developed and manufactured in Norway, utilizing canine-specific antibodies against CRP in canine serum and plasma.

    Featuring a wide measuring range, along with canine-specific reagents, calibrators and controls, precise analysis of CRP in samples from dogs can be effortlessly carried out in all labs with clinical chemistry instruments.
    • Canine-specific antibodies ensure consistent specificity to the canine CRP antigen
    • Avian origin of antibodies contributes to reduced interference
    • Calibrators and controls contain canine CRP antigen, enabling precise and specific results

    Clinical value of canine CRP
    Analysing and monitoring CRP is especially relevant in dogs with infection or inflammatory conditions where the canine CRP levels can quickly rise to more than 100 times its original concentration 1,2.
    • Early assessment of inflammatory diseases and disorders
    • Reflects the degree of inflammation
    • Monitors disease development and treatment efficacy

    Performance: The Gentian Canine CRP immunoassay:
    Sample type Serum, plasma
    Assay type PETIA
    Format Two reagents, ready to use
    Precision* Total CV < 5%
    Limit of quantification* 7 mg/L
    Reference range < 10 mg/L
    Security zone* up to 1000 mg/L
    Calibration stability* 4 weeks
    Measuring range* 10-300 mg/L
    *Instrument specific, validation results for Beckman Coulter AU400
     
    The assay is instrument dependent and can be adapted to most clinical chemistry instruments. For instrument-specific application notes, please contact us at marketing@gentian.com.

    Product range
    Product no. Product Content

    1501

    Gentian Canine CRP Reagent Kit

    R1 45 ml + R2  10.5 mL

    1519

    Gentian Canine CRP Control Kit

    2 Levels: 2 x 0.5 mL

    1551

    Gentian Canine CRP Calibrator Kit

    6 Levels: 6 x 0.5 mL



    References
    1. Pepys, et al. J Clin Invest. 2003; 111(12): 1805–1812
    2. Eckershall et al. Vet J. 2010; 185:23-27

    For more information: marketing@gentian.com